

An *in silico* structural approach to critical quality attributes assessment of biopharmaceutical products

MERCK

Saporiti S^{1,2}, Parravicini C¹, Eberini I², Centola F¹, Pergola C¹ and Sensi C¹

¹Analytical System Center of Expertise, Merck Serono, Guidonia Montecelio-Rome, Italy

²Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy



UNIVERSITÀ
DEGLI STUDI
DI MILANO

BACKGROUND

Currently, monoclonal antibodies (mAbs) are one of the most innovative class of biopharmaceuticals in development, due their ability to specifically recognize molecular targets.


Pharmaceutical companies have implemented a new strategy to control the quality profile of mAbs during the development phase: the "Quality by Design" (QbD) approach. QbD is essentially focused on critical quality attributes (CQAs) assessment. CQAs are defined as all the physical, chemical, biological or microbiological properties that should be within an appropriate limit, range, or distribution to ensure the desired product quality¹. These attributes have an impact on bioactivity, PK, immunogenicity and safety and are generally associated with the drug substance, excipients, intermediates and pharmaceutical product. In this global approach, the introduction of a structural investigation, can be very useful to early identify and assess potential CQAs (pCQAs) and for drug substance and excipients understanding.

AIMS

- Structural data collection about overall IgG1
- Identification of suitable templates
- Homology modeling of both IgG1 κ and λ and structural analysis of whole mAbs
- Identification of differences between κ and λ chains by bioinformatics tools

IGG1: STRUCTURAL INSIGHTS


IgG1s are the most expressed immunoglobulin sub-class in humans. They have a "Y-shaped" conformation, due their structural organization: two heterodimers of heavy and light chains (HC and LC), linked each other by interchain disulphide bonds, assembly to form a Y-architecture.



IGG1 λ and IGG1 κ MODELING


Due to the lack of experimental data on complete IgG1s structures, we developed an *in silico* strategy to predict the full structure of this antibodies class. We focused our study on the two subtypes of light chain, λ and κ , due their different physical-chemical properties^{3,4} and the impact of this feature on molecules bioactivity. Usually, for therapeutic mAbs, only the X-ray structure of Fab portions is solved. So, we used a homology modeling chimeric approach to obtain a prediction of whole 3D structure of proteins by a combination of different templates.

In detail, we investigated the atomistic structure of two therapeutic and commercially available mAbs: avelumab, a recently approved anti-PDL1 IgG1 λ , indicated for Merck-cell carcinoma⁵, and adalimumab, an anti-TNF α IgG1 κ used in the treatment of rheumatoid and psoriatic arthritis and for the Crohn disease⁶. We decided to use as template to model the Fab portion 4NKI.pdb and 4NYL.pdb, respectively, the X-ray structures of avelumab and adalimumab Fab. Then, we used 1HZH.pdb⁸, the only one human fully crystalized IgG1, as Fc and backbone template for both mAbs. All the computational procedures were carried out by MOE software⁹.



IGG1 κ VS IGG1 λ

The structural superposition of two models shows differences at CDRs, due to sequence heterogeneity, and a quite different orientation, mainly concentrated at the Fab C-terminal, close to hinge region. This feature may be influenced by the residue Ser216 displayed only in the λ LC of avelumab (in green) and absent in adalimumab (in grey).



CONCLUSIONS

- A chimeric approach is the most suitable to build homology models of mAbs, for both λ and κ light chains
- Ser216 of λ chains can induce slight differences in IgG1 λ , especially on the hinge region
- This structural difference could be responsible for different physical-chemical properties between IgG1 subtypes
- The structural approach proposed can be useful in CQA identification and assessment

References

1. Food and Drug Administration CDER. Guidance for industry, Q8 pharmaceutical development (May 2006)
2. Janeway CA Jr, T. P. (2001); 5th edition. New York: Garland Science
3. Zhang et al, JBC, 2013; 288(23):16371-82
4. Toughiri R et al, MABS, 2016; 1276-1285
5. Merck-Pfizer Alliance. "Merck-Pfizer Alliance Avelumab Fact Sheet"(PDF). Retrieved 2 December 2015
6. Mease PJ, Therapeutics and Clinical Risk Management. 2007; 3(1):133-148
7. Hao G et al, J Mol Recognit., 2015; (4):269-76
8. Sapphire EO et al, Science, 2001; 293(5532):1155-9
9. Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group ULC, 2018

Disclosures

Merck Serono, Guidonia Montecelio-Rome, Italy is an affiliate of Merck KGaA, Darmstadt, Germany. Please note that avelumab has been approved in various countries for the treatment of metastatic Merkel cell carcinoma and in the US for treatment of advanced urothelial carcinoma progressed after platinum-containing treatment.